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The Relationship between the Cold Chain System and Vaccine
Potency in Taiwan: (I) Live Measles Vaccine and MMR Vaccine
DER-YUAN WANG*, RUOH-ING YANG, YI-CHEN YANG, SHENG-YEN YEH,
TSO-LING CHEN, HWEI-FANG CHENG, JUEN-TIAN HSIEH AND CHIA-PO LIN

Taiwan has a long history of using vaccines in order to protect people against certain infectious diseases. Several types of vaccines have been used successfully for protecting children
from poliomyelitis, measles, and other acute infectious diseases. However, for the monovalent
measles vaccine (MV), and the trivalent measles-mumps-rubella combined vaccine (MMR
vaccine) which are made from live attenuated viruses, they are unstable unless stored at a
proper low temperature, at a certain pH level, in darkness, and combined with some specific
stabilizers. Maintaining these live virus vaccines at the recommended temperatures of +2 to
+8°°C is one of the most important limiting factors in this respect, particularly in a subtropical
climate such as in Taiwan. This study investigated and evaluated the vaccine cold chain system at different storage levels, and selected several health stations and local hospitals/pediatric
offices in each County/City of Taiwan to take samples of the MV and MMR vaccines and test
their potency during the autumn of 1997. Our results show that all of the MV samples meet
the requirements for the potency test, showing titers higher than the criteria of the WHO and
the ROC (Taiwan) national standard. The MMR vaccine also maintained its potency, with the
exception of a few mumps vaccines. This study found that the shorter the remaining term of
validity (RTV) of MMR vaccines is, the more inactivation of the mumps virus could occur.
The reason why the mumps vaccine of MMR vaccine seems unstable in Taiwan needs further
investigation. Nevertheless, the results of this study reveal that the cold chain system used in
Taiwan is satisfactory for vaccine storage.
Key words: cold chain, MV, MMR vaccine, potency test, remaining term of validity.

Since the time of Edward Jenner 200 years
ago, vaccination has been used to control several

major infectious diseases such as smallpox, diphtheria, tetanus, pertussis, poliomyelitis, measles,
mumps, and rubella(1).
Viral vaccines are highly sensitive biological
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products(2, 3), and the storage temperature, specific
pH, light, adding stabilizers such as magnesium
chloride, sorbitol, or gelatin, and other factors
influence their protective titers(4,5). The immunogenicity of live virus vaccines, unlike the inactivated ones, depends on the retention of a sufficient amount of live viruses to establish an infection in the susceptible recipient(6). The live viruses
of these vaccines, even when they were dried,
show loss of infectivity by storage, and the rate
for such loss increases as the temperature is elevated. Dried live virus vaccines should be stored
continuously in a more stable cold chain system
including the transport mechanism and the controlled refrigeration up to the time of delivery to
the recipient(7,8). Therefore, it is important to provide maximum stability for live virus vaccines
during storage. The measles vaccine (MV) and the
combined measles-mumps-rubella vaccine (MMR
vaccine) investigated here are dried live attenuated virus vaccines and should be transported and
stored under +2 to +8°C conditions to maintain
their titers(9,10). Maintaining the MV and MMR
vaccine at the recommended temperatures
between +2 to +8°C is one of the most important
limiting factors in Taiwan which has a semi-tropical climate.(11)
Vaccines have been used for many years to
protect people against certain communicable diseases in Taiwan. The MV and MMR vaccines
have long been used to protect children from
measles, mumps and rubella. The reported incidence of measles decreased steadily after the wide
use of live measles vaccine in 1978 in the Taiwan
area. However, island-wide outbreaks of measles
still occur every 2-3 years. Most of the infected
had not been vaccinated. After rubella vaccine
was licensed in 1969, vaccination programs in the
U.S. resulted in a great reduction in the reported
cases of rubella and congenital rubella syndrome
(CRS)(12). Since 1984, the live rubella virus vaccine has been widely given to junior high school
girls in the Taiwan area. As a result, only a few
reported cases of rubella and CRS occurred during
the period 1988 to 1993. In addition, the reported
incidence of mumps in the Taiwan area decreased

after the introduction of MMR vaccine in 1992.
To improve living standards and make universal
the practice of immunization, the Department of
Health of the Executive Yuan initiated a plan for
the elimination of poliomyelitis, CRS, measles,
and neonatal tetanus in January 1991. An important part of the plan was to strengthen measures to
safeguard the potency of vaccines. For example,
through rigorous testings of each vaccine batch
and the strict control of temperature, etc, the
potency of vaccines could be maintained at a satisfactory level. However, it is still unknown
whether there is a close relationship between the
cold chain system and vaccine potency in Taiwan.
The cold chain system in transportation and
storage of vaccines in the Taiwan area is a threelevel storage/transport system (Fig. 1). Level I is
composed of the health bureaus of Taipei City,
Kaohsiung City and 21 Counties/Cities of Taiwan
province; level II is composed of the health stations of each County/City; and level III is composed of local hospitals/pediatric offices and the
health rooms of the City/County health station.
The vaccines are transported to level I storage
areas and stored in large-scale freezers after they
have been qualified by testing at the National
Laboratories of Foods and Drugs. At the request
of health workers from level II, the vaccine is then
transported and stored in the refrigerators of level
II, for inoculation of children and adults in those
areas. Finally, part of the vaccine is transported to
level III when needed.
Several investigations have demonstrated that
the MV and MMR vaccines have good efficacy(1317). Pabst et al. reported that both cellular and
humoral immune responses were induced by
MMR vaccination (14) . However, it was still
unknown whether hot climate, the failure of a
refrigerator mechanical system, a breakdown in
the transport system, and other limiting factors in
the cold chain system might affect the vaccine
storage conditions and lower their potency(18). In
this study, we attempted to find a correlation
between the vaccine potency and the cold chain
system in Taiwan, and identify the possible factors
affecting vaccine potency. The MV and MMR
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vaccines were randomly sampled from the level II
and III areas in our epidemic prevention system
and tested for their potency. Our results demonstrated that the MV samples met the requirements

Level 1 Storage Areas

in the potency test. Their titers showed no significant difference between the level II and III storage
areas. All the results demonstrated that the MV
was stable enough and not influenced by the vari-

Level 2 Storage Areas

Level 3 Storage Areas

Figure 1. The flow chart of vaccine transport and storage in Taiwan’s cold chain system.
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able temperature conditions. The MMR vaccine
maintained potency except for some dissatisfactory cases with lower titers in the mumps vaccine.
We found that the short length of RTV was the
major factor for the degradation of mumps potency in the MMR vaccine.

5 to 12 generations.
IV. Potency Test
The potency test was conducted according to
the methods for potency testing of vaccines used
in the World Health Organization’s (WHO)
expanded program on immunization(19).
(I) Measles/Mumps Vaccine Potency Test

I. Materials
Minimum essential medium (MEM) containing Earle’s salts, L-glutamine, and sodium bicarbonate, heat-inactivated and qualified fetal bovine
serum (FBS) , antibiotics (100x, lyophilized) and
trypsin/EDTA solution were all purchased from
Gibco BRL (Grand Island, NY). The neutralizing
antisera of measles, mumps, and rubella viruses as
well as the house standards of measles vaccine,
mumps vaccine, and rubella vaccine were from
Merck Sharp and Dohme (RAHWAY, NJ). The
microtiter plates, tissue culture flasks, and other
plastic accessories were from Corning/Costar
(Nagog Park Action, MA).
II. Vaccine Samples
The freeze-dried measles vaccine and combined MMR vaccine were sampled from the
health stations and health rooms/local hospitals/
pediatric offices at 23 Counties/Cities in the
Taiwan area. All vaccine samples were coded and
shipped with dry ice, and stored at -20°C before
testing.
III. Cell and Cell Culture
All cells purchased from American Tissue
Culture Collection (ATCC) were established into
the master cell bank (MCB) and working cell
bank (WCB) in our laboratory. Vero cells (ATCC
CCL-81) were used for the potency tests of
measles vaccine and mumps vaccine, while RK13 cells (ATCC CCL-37) were used for rubella
vaccine assay. All stock cultures were prepared
from WBC. They were maintained in MEM supplemented with 10% FBS in a humidified incubator at 37°C under 5% CO2 condition and passed at

The potency of measles/mumps vaccine samples was tested by an in vitro microtitration assay.
Serial dilutions of these samples and the reference
standards preparation were inoculated in rows of
10 wells of microtiter plates, together with
trypsinized Vero cell suspension. To avoid interference, mumps and rubella vaccine viruses (for
measles titration) or measles and rubella vaccine
viruses (for mumps titration) were neutralized by
the addition of appropriate antisera. The plates
were incubated at 35°C/5% CO2 for 10~12 days.
At the end of the incubation period, the numbers
of the specific viral cytopathic effect (CPE) were
counted and recorded. The CCID50 (or TCID50)
per human dose was calculated using the Reed
and Muench calculation method(20).
(II) Rubella Vaccine Potency Test
The potency of rubella vaccine samples was
also tested by the in vitro microtitration assay.
Serial dilutions of the samples and the reference
standard preparation were inoculated in rows of
10 wells of microtiter plates, together with
trypsinized RK-13 cell suspension. The measles
and mumps vaccine viruses were neutralized by
the addition of appropriate antisera to avoid interference. The plates were incubated at 33°C/5%
CO2 for 10~14 days. At the end of the incubation
period, the CPE numbers were counted and
recorded. The CCID50 (or TCID 50) per human
dose was calculated using the Reed and Muench
calculation method(20).
V. Statistical Analysis
The SPSS statistic software was used to analyze experimental results. The student’s T test and
the Fisher’s protected LSD (FPLSD) multiple
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comparisons were used for analyzing the results
of the MV and MMR vaccine potency tests.

During 1997 Nov to 1998 Feb, we randomly
selected the health stations, health rooms, local
hospitals, and pediatric offices from the level II
and III storage areas in Taiwan as the sampling
areas. In total, we tested the 94 samples of MV
vaccine and 40 samples of MMR vaccine from the
above selected districts. After the samples were
collected, they were immediately transported to
our laboratory for vaccine potency testing.

vaccine we tested could be more heat-stable than
the MMR vaccines. The cold chain system in
Taiwan has the ability to maintain the potency of
the measles vaccine during the remaining term of
validity (RTV).
II. MMR Vaccine Potency
The MMR vaccine consists of the monovalent
measles vaccine, the monovalent mumps vaccine,
and the monovalent rubella vaccine. In this study,
we used the neutralizing antisera of these viruses
to test the monovalent virus potency.
(I) Measles Vaccine Potency

In our testing results, all of the MV samples
are qualified in the potency test and their average
titer is 3.490 ± 0.229 Log10TCID50/dose (Table 1).
The titers are higher than the criteria of the WHO
and the national standard of the Republic of China
(ROC) on Taiwan (not less than 3.0 Log10TCID50/
dose/0.5mL or 1,000 TCID 50 /dose/0.5mL).
According to the temperature records of the sampling areas, the average storage temperature in the
level II area (4.75°C) is lower than in level III
(6.64°C). The temperatures of both storage areas
are still in the normal range (2~8°C). We used the
student’s T statistic analysis to compare the potency of the vaccines stored in levels II and III. Table
2 shows that the measles potency between these
two storage areas has also no significant differences (P > 0.05). It is possible that the higher
quantities of the measles virus are filled in the
final products. Therefore, the monovalent measles

Like MV, our results show that the average
measles potency of MMR vaccine is 3.256 ±
0.229 Log10TCID50/dose (Table 3). The measles
potency of all MMR samples are higher than the
criteria of the WHO and the ROC national standard (not less than 3.0 Log10TCID50/dose/0.5mL
or 1,000 TCID50/dose/0.5mL). Already aware that
the average storage temperature in the level II area
was lower than in the level III area, this study
sought to find out if any difference of measles
potency between the different storage areas exists.
Table 4 shows that the measles potency of MMR
samples stored in level II are higher than in level
III. These differences are significant (P < 0.05).
Although all the measles potency results are satisfactory, our findings still show that the measles
virus in the MMR vaccine is more affected by
heat than the monovalent MV. Furthermore, the
other two viruses may influence the measles
potency in MMR vaccines. This could explain
why our results found the monovalent MV poten-

Table 1. The Average Potency of the Monovalent
Measles Vaccines

Table 2. The potency of the measles vaccine sampled from the level II and III storage areas

I. Measles Vaccine Potency

Average
Potency
(Log10TCID50/dose/0.5 mL)
Measles Vaccine Sample
3.490 ± 0.229a
Reference Measles Vaccine
3.388 ± 0.038
a The average potency of the monovalent measles
vaccines was shown as mean ± standard deviation.

Storage Area

Vaccine Potency
(Log10TCID50/dose/0.5 mL)

Level II
Level III

3.518 ± 0.238a
3.468 ± 0.234

a

The statistical analysis was done by student's T
test and there were no significant differences (P
= 0.549).
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cy to be higher than the measles potency in the
MMR vaccine.
(II) Mumps Vaccine Potency
This study shows that the average mumps
potency of MMR vaccine is 4.196 ± 0.303
Log10TCID50/dose (Table 3). This is lower than
the criteria of the WHO and the ROC national
standard (not less than 4.3 Log 10TCID 50/dose/
0.5mL or 20,000 TCID50/dose/0.5mL). According
to the results of student's T test for statistical
analysis, there is no significant difference between
the vaccines sampled from level II and III (Table
4). The lower average mumps potency is caused
by some dissatisfactory vaccines sampled from
the individual storage unit. However, the temperatures recorded in these health stations, health
rooms, and local hospitals/pediatric offices are
normal.
In order to find the possible factors that affect
the mumps potency of MMR vaccines, we analyzed other data including the personal error of
temperature recording, transport conditions, the
fluctuation of temperature changes in the refrigerator and the condition of the vaccine itself. It was
found that only the RTV factor concerns the
decreased potency of mumps vaccine. Table 5
shows that most of the disqualified MMR vac-

cines belong to two production lots, and these are
relatively closer to the expiration date than are the
qualified ones. The RTV of the MMR vaccines we
sampled, were divided into three groups: 1~6
months, 7~12 months, and over 12 months. The
ANOVA analysis shown in Table 6-1 indicates
significant differences among the RTV of MMR
vaccines. The FPLSD results (Table 6-2) demonstrate that the MMR vaccines are closer to the end
of the vaccine lifetimes and the mumps potency is
more degraded. The difference of mumps potency
between the newest MMR vaccines and the oldest
ones is at 1.3 Log 10 TCID 50 /dose/0.5 mL.
However, Dr. W. J. McAleer and colleagues have
demonstrated that the infective degradation rate of
mumps virus in the MMR vaccine are at 0.2~0.3
Log10TCID50/0.1 mL when the vaccines are stored
at 2~8°C(21). In addition, it is known that the minimal infectious dose of virus required to immunize
a susceptible human being has been measured in
titrations in man and are 20 TCID 50 for the
measles virus (22) , 317 TCID 50 for the mumps
virus(23), and 40 TCID50 for the rubella virus(24,
25). Our study shows that the mumps virus of the
MMR vaccine are more unstable than the other
two. We suggest that there are two possible explanations: (1) It is due to the stabilizer, sorbitolgelatin complex used in the MMR vaccine(26, 27).

Table 3. The average monovalent vaccine potency of the MMR vaccines
Vaccine Potency (Log10TCID50/dose/0.5 mL)
Measles
Mumps
Rubella
MMR Vaccine Sample
Reference Vaccine
House Standarda
a

3.256 ± 0.155
3.394 ± 0.213
3.667 ± 0.911

4.196 ± 0.303
4.530 ± 0.243
4.937 ± 0.970

3.246 ± 0.157
3.402 ± 0.119
3.730 ± 0.806

The house standards were provided from Merck Sharp and Dohme (measles, Lot. 10; mumps, Lot. 8; rubella, Lot. 7).

Table 4. The monovalent vaccine potency of the MMR vaccines sampled from the level II and III storage
area
Vaccine Potency (Log10TCID50/dose/0.5 mL)
Measles
Mumps
Rubella
Level II
Level III
a

3.313 ± 0.135a
3.230 ± 0.261

4.210 ± 0.150
4.190 ± 0.068

3.264 ± 0.201
3.237 ± 0.132

The potency difference between the level II and III storage areas was statistically significant (P = 0.029).
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This stabilizer is not sufficient to stabilize the
MMR vaccine in the hot climate of Taiwan.
Therefore, the mumps virus can not maintain
potency for 2 years. (2) The mumps virus in the
MMR vaccine is highly heat-sensitive. Although
the average storage temperature is at normal
range, the temperature of the refrigerator, which
stored dissatisfactory vaccines, may have gone
through extreme temperature variations many
times each day. This variation could lead to
mumps virus degradation. Furthermore, it is not
clear whether these dissatisfactory MMR vaccines
still elicit enough immune protection against
mumps disease. Further investigation is needed to
elucidate these problems.
(III) Rubella Vaccine Potency
All the rubella potency of MMR vaccines is
qualified for the criteria of the WHO and the ROC
national standards (not less than 3.0 Log10TCID50/
dose/0.5mL or 1,000 TCID50/dose/0.5mL). The
average rubella potency of MMR vaccines is
3.490 ± 0.229 Log 10TCID 50/dose (Table 5-1).
There are no significant differences of rubella
potency between the MMR vaccines sampled

from the level II and III storage areas (Table 5-2).
The rubella potency is still qualified even though
their RTV was very short. It was found that the
measles virus and rubella virus in the MMR vaccine are very stable in our cold chain system.

In this study, we found that the cold chain system used in Taiwan is suitable to maintaining the
measles vaccine. There are no significantly different temperature conditions between levels II and
III even though the difference reaches close to

Table 5. The remaining term of validity (RTV) of
the MMR vaccines
Qualified MMR Disqualified MMR
Vaccines
Vaccines
Average RTV
(months)
a

7.065a

4.926

The RTV difference between the qualified MMR
vaccines and disqualified ones was statistically
significant (P = 0.003).

Table 6-1. The ANOVA analysis of the mumps vaccine potency in the MMR vaccines among the RTV
groups
Total
RTV Group
Error
a

Sum of Squares

df

Mean Squarm

F value

7.730
0.795
6.935

2
82
84

0.397
0.0846

4.699a

The mumps potency difference among the RTV groups was statistically significant (P = 0.012).

Table 6-2. Grouping of ranked average mumps potency with FPLSD

The Mumps Potency of MMR Vaccinesa
a

A (>12 months)

RTV Groupsb
B (7~12 months)

C (1~6 months)

4.378 c

4.367d

4.143e

The mumps vaccine potency of the MMR vaccines was shown as Log10TCID50/dose.
The RTVs of the MMR vaccines were grouped into three groups. The group A, B, and C were designed to
the over 12 months, the 7~12 months, and the 1~6 months, respectively.
c The rank of average mumps potency between the RTV groups was A > B > C.
d The mumps potency difference between the group A and B was not significant (P = 0.937) and underlined
by the same line.
e The mumps potency difference between the group B and group C was statistically significant (P = 0.010).
b
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2°C. The cold chain system in Taiwan can provide
a relatively stable condition for measles vaccine
storage. In addition, the MMR vaccines are also
stable in this cold chain system except for a few
mumps vaccines. Our results indicate that the
shorter the RTV of MMR vaccines is, the more
inactivation of the mumps virus occurs. It seems
that the mumps virus of the MMR vaccine is less
stable in Taiwan. Whether this is caused by insufficiency of the stabilizer in the mumps vaccine, or
the virus strain of mumps vaccine is too heat-sensitive or other factors needs more investigation to
clarify.
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